A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Abacavir Sulfate, Dolutegravir Sodium, Lamivudine (Triumeq)

Abacavir Sulfate, Dolutegravir Sodium, Lamivudine suppresses hepatitis B virus replication.

First FDA approval2014-08-22
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$130.00/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$130.00
Across all dosage forms in distribution.
Highest NADAC
$130.00
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Abacavir Sulfate, Dolutegravir Sodium, Lamivudine used for?

Abacavir Sulfate, Dolutegravir Sodium, Lamivudine suppresses hepatitis B virus replication.

Is there a generic for Abacavir Sulfate, Dolutegravir Sodium, Lamivudine?

No. Abacavir Sulfate, Dolutegravir Sodium, Lamivudine is brand-only with no generic equivalents currently in market.

How much does my plan pay for Abacavir Sulfate, Dolutegravir Sodium, Lamivudine?

Across 329 Part D plans, Abacavir Sulfate, Dolutegravir Sodium, Lamivudine averages $130.00/unit (NADAC). Lowest available: $130.00/unit. Highest in distribution: $130.00/unit.

Is Abacavir Sulfate, Dolutegravir Sodium, Lamivudine on the FDA shortage list?

No. Abacavir Sulfate, Dolutegravir Sodium, Lamivudine is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor6 alternatives in D1
01
Abacavir , Lamivudine and Zidovudine
Brand: ABACAVIR, LAMIVUDINE AND ZIDOVUDINE
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Abacavir and Lamivudine
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
$1.26Lowest NADAC
5Generic mfrs
CY24 Part D spend
Compare →
03
Dolutegravir and Lamivudine
Brand: Dovato
$105.29Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
04
Entecavir
Brand: BARACLUDE
$0.222Lowest NADAC
8Generic mfrs
$44.1MCY24 Part D spend
Compare →
05
Lamivudine
Brand: EPIVIR
$0.249Lowest NADAC
10Generic mfrs
$8.4MCY24 Part D spend
Compare →
06
Lamivudine Oral
Brand: lamivudine
$0.249Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.